Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

NCT03894046 is registered in ClinicalTrials.gov with Entasis Therapeutics as lead sponsor.

NCT NCT03894046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03894046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
Lead sponsor
Entasis Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
September 5, 2019
Completion date
July 26, 2021
Enrollment
207 (actual)
Sites
90

Conditions

As the registry lists them; a condition with its own page is linked.

acinetobacter baumannii-calcoaceticus complex, bacteremia, colistin resistant abc, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia